tACS plus stable medication for teens with major depressive disorder
Official title: Efficacy and Safety of Transcranial Alternating Current Stimulation (tACS) Combined With Stable Medication in Adolescents With Depression: A Randomized, Double-Blind, Controlled Pilot Study
Run by First Affiliated Hospital of Chongqing Medical University · NCT07185451 · Data updated 2026-11-12
This pilot study tests whether adding transcranial alternating current stimulation to a teen’s ongoing antidepressant treatment can help reduce depressive symptoms and is safe to use.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 12 Years to 18 Years |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | First Affiliated Hospital of Chongqing Medical University Academic / other |
| Locations | 1 site (Chongqing, Chongqing Municipality) |
| Status | Recruiting |
| Started | October 1, 2025 |
| Main results expected | March 30, 2027 |
| Study ends | October 1, 2027 |
| Registry record updated | October 5, 2026 |
| Trial ID | NCT07185451 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adolescents aged 12-18 with a current depressive episode, a CDRS-R score of 40 or higher, and stable antidepressant treatment for at least 4 weeks.
✕Probably not a fit
Participants with significant psychiatric comorbidity beyond anxiety disorders or with certain neurological or systemic illnesses may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized, double-blind, sham-controlled pilot evaluates transcranial alternating current stimulation (tACS) as an adjunct to stable pharmacotherapy in adolescents with major depressive disorder. Thirty participants aged 12-18 will be assigned to active or sham tACS for 20 sessions over four weeks, using the NEXALIN ADI device. Primary goals focus on feasibility, adherence, retention, and safety, with exploratory outcomes including changes in CDRS-R scores and response/remission rates. Assessments include clinical, cognitive, and brain-function measures, with follow-up through Week 16.
Why it matters
Potential benefit: If successful, this approach could offer an additional, non-drug option to help reduce depressive symptoms in adolescents already receiving medication.
How similar studies have gone: Prior neurostimulation trials in mood disorders have shown potential benefits, but this adolescent, adjunctive tACS approach is exploratory and remains to be proven.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age 12-18 years. 2. Meet DSM-5 diagnostic criteria for a current depressive episode, as confirmed by the K-SADS-PL. 3. Children's Depression Rating Scale-Revised (CDRS-R) score ≥40 at baseline. 4. Stable psychotropic medication treatment for at least 4 weeks prior to enrollment and willingness to continue the same regimen throughout the study. Exclusion Criteria: 1. Psychiatric comorbidities other than anxiety disorders. 2. Depression with psychotic features. 3. Young Mania Rating Scale (YMRS) score \>13. 4. History of neurological disorders (e.g., epilepsy, traumatic brain injury) or severe physical illnesses (e.g., thyroid disease, lupus, diabetes, significant liver, kidney, or lung impairment, major trauma). 5. Previous treatment with electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), transcranial direct current stimulation (tDCS), tACS, or other neurostimulation therapies. 6. Current use of antiepileptic drugs or high-dose benzodiazepines. 7. History of alcohol or substance abuse or dependence. 8. Pregnant or breastfeeding females. 9. Contraindications to MRI. 10. Current high suicide risk.
Where it's running
-
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China Recruiting
Study contacts
- Study coordinator: Xinyu Zhou
- Email: zhouxinyu@cqmu.edu.cn
- Phone: 15823996993
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Understanding how the orbitofrontal cortex guides approach vs. avoidance in depression
This study tests how different parts of the orbitofrontal cortex influence whether people pursue rewards or risk loss, and whether this pattern is altered in Major Depressive Disorder.
-
Health education program to help depression in older adults and caregivers in Ho Chi Minh City
A community-based education program for people 60+ and their caregivers is being tested to see if it can lower depression and improve quality of life compared with standard care.
-
Prucalopride for low mood: testing a 5-HT4 receptor activator for cognition and sleep
This study tests whether prucalopride, a 5-HT4 receptor drug, can improve thinking and sleep in adults with low mood or major depressive disorder compared to a placebo.
-
Pre-visit Companion Brief: a primary care AI-assisted check for depression and anxiety
This pilot tests an AI-powered pre-visit assessment that creates a concise Companion Brief for clinicians to help identify depression and anxiety during routine primary care.
-
Medically tailored groceries to help depression in people with food insecurity
This trial tests whether giving medically tailored groceries for six months can reduce depressive symptoms in adults who have depression and struggle with access to food.
-
Health and Work Ability After Inpatient Treatment for Stress-Related Disorders: Follow-Up of the HARMODI Cohort
This study follows people who had inpatient treatment for stress-related disorders to see how their health and ability to work change over the next three years and what factors help them return to work.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.